Overbrook Management Corp lowered its stake in Johnson & Johnson (NYSE:JNJ) by 3.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,498 shares of the company’s stock after selling 2,510 shares during the quarter. Johnson & Johnson comprises about 1.8% of Overbrook Management Corp’s portfolio, making the stock its 16th biggest holding. Overbrook Management Corp’s holdings in Johnson & Johnson were worth $8,532,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $177,000. Finally, Ullmann Financial Group Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $186,000. 65.93% of the stock is currently owned by institutional investors.
WARNING: “Johnson & Johnson (JNJ) Holdings Reduced by Overbrook Management Corp” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/11/15/johnson-johnson-jnj-holdings-reduced-by-overbrook-management-corp.html.
Several brokerages have recently issued reports on JNJ. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target on the stock in a research report on Monday, October 30th. Citigroup Inc. increased their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Jefferies Group LLC increased their price target on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Barclays PLC increased their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $143.70.
Johnson & Johnson (NYSE:JNJ) opened at $139.49 on Wednesday. The company has a market cap of $375,468.03, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.68 earnings per share. equities research analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.41%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.